US Patent Issued to MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, CHARITE -UNIVERSITATSMEDIZIN BERLIN on Nov. 25 for "CD5 specific T cell receptor cell or gene therapy" (German Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,903, issued on Nov. 25, was assigned to MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (Berlin) and CHARITE -UNIVERSITATSMEDIZIN BERLIN (Berlin).

"CD5 specific T cell receptor cell or gene therapy" was invented by Antonio Pezzutto (Berlin), Thomas Blankenstein (Berlin), Nese Cakmak-Gorur (Berlin) and Elmehdi Belbaraka (Berlin).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides nucleic acids encoding at least one TCR alpha or beta chain construct of a TCR ...